D-methyldopa - IM Therapeutics
Alternative Names: IMT-002Latest Information Update: 28 Jul 2023
At a glance
- Originator University of Colorado at Denver
- Developer IM Therapeutics
- Class Amines; Antihyperglycaemics; Catechols; Propionic acids; Small molecules
- Mechanism of Action Alpha 2 adrenergic receptor agonists; HLA-DQ8 antigen inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Coeliac disease; Type 1 diabetes mellitus
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus in USA (PO)
- 28 Dec 2021 No recent reports of development identified for preclinical development in Coeliac disease in USA (PO)
- 22 Jul 2021 Safety, pharmacokinetics and pharmacodynamics data from phase Ib trial in Type 1 diabetes mellitus released by IM Therapeutics